One study among BPD patients who underwent 12-weeks of DBT treatment found that while there were no significant differences in DNA methylation of APBA3 and MCF2 differences between patients with BPD and healthy controls, there was a significant correlation between the methylation status of APBA3 and MCF2 and therapy outcome. This evidence concerns the gene APBA3 and Borderline personality disorder.